U
U. Nitz
Researcher at University of Düsseldorf
Publications - 99
Citations - 6427
U. Nitz is an academic researcher from University of Düsseldorf. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 14, co-authored 73 publications receiving 5826 citations. Previous affiliations of U. Nitz include Bethesda Hospital.
Papers
More filters
Journal ArticleDOI
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Martine Piccart-Gebhart,Marion Procter,Brian Leyland-Jones,Aron Goldhirsch,Michael Untch,Ian E. Smith,Luca Gianni,José Baselga,Richard Bell,Christian Jackisch,David Cameron,Mitch Dowsett,Carlos H. Barrios,Günther G. Steger,Chiun-Shen Huang,Martin Andersson,Moshe Inbar,Mikhail Lichinitser,István Láng,U. Nitz,Hiroji Iwata,C Thomssen,Caroline Lohrisch,Thomas M. Suter,Josef Rüschoff,Tamás Süto ý,Victoria Greatorex,Carol Ward,Eleanor McFadden,M. Stella Dolci,Richard D. Gelber +30 more
TL;DR: One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.
Journal ArticleDOI
Triple-negative breast cancer—current status and future directions
TL;DR: Triple-negative breast cancer is defined by a lack of expression of both estrogen and progesterone receptor as well as human epidermal growth factor receptor 2, characterized by distinct molecular, histological and clinical features including a particularly unfavorable prognosis despite increased sensitivity to standard cytotoxic chemotherapy regimens.
Journal ArticleDOI
Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade.
Philipp Müller,Matthias Kreuzaler,Tarik A. Khan,Daniela S. Thommen,Daniela S. Thommen,Kea Martin,Katharina Glatz,Spasenija Savic,Nadia Harbeck,U. Nitz,U. Nitz,Oleg Gluz,Michael von Bergwelt-Baildon,Hans Kreipe,Sai T. Reddy,Matthias Christgen,Alfred Zippelius,Alfred Zippelius +17 more
TL;DR: T-DM1 is particularly effective in eliciting antitumor immunity in patients with early breast cancer and in a HER2-expressing orthotopic tumor model, and it is shown that it can be used in combination therapy.
Journal ArticleDOI
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial
O Gluz,U. Nitz,Nadia Harbeck,E. Ting,Ronald E. Kates,Alexander Herr,Walter Lindemann,C. Jackisch,Wolfgang E. Berdel,Hartmut Kirchner,Bernd Metzner,F. Werner,G. Schütt,M. Frick,Christopher Poremba,Raihana Diallo-Danebrock,Svjetlana Mohrmann +16 more
TL;DR: Tandem HD improves both EFS and OS in HRBC, and this therapy effect may be partly attributable to superior efficacy in the subgroup of triple-negative tumors and/or G3 with their poor prognostic marker profile.
Journal Article
Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
A. du Bois,H.-J. Lück,Werner Meier,Volker Möbus,SD Costa,Barbara Richter,M. Warm,Thomas Bauknecht,W. Schröder,S. Olbricht,U. Nitz,C. Jackisch +11 more
TL;DR: In this article, an interim analysis after 15 months' accrual of the prospectively randomized German Arbeitsgemeinschaft Gynakologische Onkologie (AGO) study is presented.